Kadmon Holdings Inc (KDMN) Receives $13.23 Consensus Target Price from Analysts
Shares of Kadmon Holdings Inc (NYSE:KDMN) have earned an average rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $13.23.
A number of equities research analysts have recently commented on KDMN shares. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Wednesday, July 11th. HC Wainwright set a $25.00 price objective on shares of Kadmon and gave the stock a “buy” rating in a research note on Monday, August 13th. Finally, WBB Securities raised shares of Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price objective on the stock in a research note on Wednesday.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp grew its stake in shares of Kadmon by 395.3% during the 2nd quarter. Northern Trust Corp now owns 791,781 shares of the company’s stock worth $3,159,000 after purchasing an additional 631,914 shares during the period. Bank of New York Mellon Corp grew its stake in Kadmon by 191.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 198,063 shares of the company’s stock valued at $790,000 after acquiring an additional 130,096 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Kadmon in the 2nd quarter valued at $148,000. Metropolitan Life Insurance Co. NY acquired a new stake in Kadmon in the 2nd quarter valued at $105,000. Finally, Acuta Capital Partners LLC grew its stake in Kadmon by 52.3% in the 2nd quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock valued at $36,149,000 after acquiring an additional 3,110,014 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Kadmon (NYSE:KDMN) last issued its quarterly earnings results on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.50. The business had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.90 million. Analysts expect that Kadmon will post -0.94 earnings per share for the current year.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.